BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Safinamide regulatory update

Newron and Zambon said Zambon submitted an MAA to EMA for safinamide to treat Parkinson's disease. The MAA covers safinamide as add-on therapy to a stable dose of a dopamine agonist for patients with early...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >